Patent ID: 7553934

Claim:
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a mutant Factor VII (FVII) or mutant Factor VIIa (FVIIa) polypeptide, wherein said mutant FVII or mutant FVIIa polypeptide comprises a modified γ-carboxyglutamic (GLA) domain that enhances membrane binding affinity of said mutant FVII or mutant FVIIa polypeptide relative to a wild type human Factor VII (hFVII) or wild type human Factor VIIa (hFVIIa) polypeptide, wherein said modified GLA domain comprises an amino acid sequence that differs form the amino acid sequence of the GLA domain of wild type hFVII or wild type hFVIIa polypeptide shown in SEQ ID NO: 3 in 1 to 5 amino acid substitutions, wherein the proline residue at amino acid position 10 of SEQ ID NO: 3 is substituted with a glutamine, aspartic acid or glutamic acid residue in the modified GLA domain.